DIAKONOS ONCOLOGY
Live / Applied — First extension granted (statement of use) (as of 04 Jun 2025)
What this means for you
Not registered yet, but its 03 Nov 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98253483
- Mark type
- Stylized text
- Filed
- 03 Nov 2023
- Published for opposition
- 22 Oct 2024
- Attorney of record
- Andrea Shannon
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use consisting of immunotherapy agents for the treatment and prevention of cancer; vaccine preparations
- Class 042 — Scientific and technological services: Providing medical research and scientific research information in the field of oncology; medical research in the field of oncology; research and development of immunotherapy drugs
Owner
- Diakonos Oncology Corporation, Houston, TX, US
- Diakonos Oncology Corporation, Houston, TX, US
Prosecution history
- 14 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Jun 2025 — SOU EXTENSION 1 GRANTED
- 03 Jun 2025 — SOU EXTENSION 1 FILED
- 03 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 22 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Oct 2024 — PUBLISHED FOR OPPOSITION
- 02 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Sept 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Sept 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Sept 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 17 Jun 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 Jun 2024 — NON-FINAL ACTION E-MAILED